Golden
Editas Medicine

Editas Medicine

Editas Medicine is a genome editing company founded in 2013 that is using CRISPR technology to treat patients with genetically defined diseases.

Editas Medicine has developed a proprietary genome editing platform based on CRISPR using different engineered variants of CRISPR effector nucleases Cas9 and Cpf1 (also known as Cas12a). The company is working on editing efficiency, control of cutting and delivery of treatment to sight of disease. Editas Medicine is in the discovery stage of developing CRISPR gene edit treatments for the following conditions:

Leber Congenital Amaurosis 10

Usher Syndrome 2a

HSV-1

T Cells for cancer treatments

Beta Thalassemia

Sickle Cell

Cystic Fibrosis

Alpha-I Antitrypsin Deficiency

Editas Medicine was previously founded under the name Gengine by Feng Zhang, George Church, Keith Joung, David Liu all from The Broad Institute at MIT and Harvard along with Jennifer Doudna from University of California, Berkeley. Jennifer Doudna left and co-founded Intellia Therapeutics.

Timeline

People

Name
Role
Related Golden topics

Andrew Hack, M.D., Ph.D.

CFO

Charlene Stern, J.D., Ph.D.

Vice President and Head of Legal

Charles Albright, Ph.D.

CSO

Katrine Bosley

CEO

Semi Trotto

Vice President and Head of Human Resources

Timothy D. Hunt, J.D.

Senior Vice President of Corporate Affairs

Vic Myer, Ph.D.

Chief Technology Officer

Further reading

Title
Author
Link
Type

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References